España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Celldex Therapeutics
CLDX
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$25.13
0.36
1.45%
At close: -
$25.13
0.00
0.00%
After Hours: Dec 24, 1:00 PM EDT
Get Report
Comment
Celldex Therapeutics (CLDX) Forecast
News
Earnings
Celldex Therapeutics (CLDX) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Celldex Therapeutics (NASDAQ:CLDX) Stock
Celldex Therapeutics Stock (NASDAQ: CLDX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, December 20, 2024
What Analysts Are Saying About Celldex Therapeutics Stock
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Celldex...
Benzinga Newsdesk
Thursday, December 19, 2024
HC Wainwright & Co. Reiterates Buy on Celldex...
Benzinga Newsdesk
Celldex Launches Phase 2 Study Of Barzolvolim...
Benzinga Newsdesk
Wednesday, November 20, 2024
Celldex Therapeutics Doses First Patient In P...
Benzinga Newsdesk
Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Celldex...
Benzinga Newsdesk
Thursday, November 07, 2024
HC Wainwright & Co. Reiterates Buy on Celldex...
Benzinga Newsdesk
Monday, October 28, 2024
Analyst Expectations For Celldex Therapeutics's Future
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Celldex...
Benzinga Newsdesk
Friday, October 25, 2024
Celldex Announces Upcoming Late Breaking Oral...
Benzinga Newsdesk
Monday, October 07, 2024
Citigroup Initiates Coverage On Celldex Thera...
Benzinga Newsdesk
Monday, September 30, 2024
Goldman Sachs Initiates Coverage On Celldex T...
Benzinga Newsdesk
Friday, September 27, 2024
This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Avi Kapoor
Wolfe Research Downgrades Celldex Therapeutic...
Benzinga Newsdesk
Thursday, September 26, 2024
HC Wainwright & Co. Reiterates Buy on Celldex...
Benzinga Newsdesk
Wednesday, September 25, 2024
A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics
Benzinga Insights
Wolfe Research Reiterates Outperform on Celld...
Benzinga Newsdesk
Celldex Therapeutics shares are trading lower...
Benzinga Newsdesk
Celldex Therapeutics Shares Resumed Trade
Benzinga Newsdesk
Chief Medical Officer Diane C. Young, Of Cell...
Benzinga Newsdesk
Celldex Therapeutics Reports Safety Concerns ...
Benzinga Newsdesk
Celldex Therapeutics Presents 52-Week Results...
Benzinga Newsdesk
Friday, September 20, 2024
Cantor Fitzgerald Reiterates Overweight on Ce...
Benzinga Newsdesk
Wednesday, September 18, 2024
Cantor Fitzgerald Reiterates Overweight on Ce...
Benzinga Newsdesk
Monday, September 16, 2024
Cantor Fitzgerald Reiterates Overweight on Ce...
Benzinga Newsdesk
Celldex Announces Upcoming Late Breaking Oral...
Benzinga Newsdesk
Monday, September 09, 2024
The Analyst Verdict: Celldex Therapeutics In The Eyes Of 7 Experts
Benzinga Insights
Cantor Fitzgerald Reiterates Overweight on Ce...
Benzinga Newsdesk
Monday, August 12, 2024
Wells Fargo Maintains Equal-Weight on Celldex...
Benzinga Newsdesk
7 Analysts Have This To Say About Celldex Therapeutics
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Celldex...
Benzinga Newsdesk
Thursday, August 08, 2024
Celldex Therapeutics Q2 EPS $(0.54) Beats $(0...
Benzinga Newsdesk
Tuesday, July 30, 2024
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
Cantor Fitzgerald Reiterates Overweight on Ce...
Benzinga Newsdesk
Lattice Semiconductor Posts Weak Q2 Results, Joins Symbotic, Woodward And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Avi Kapoor
HC Wainwright & Co. Reiterates Buy on Celldex...
Benzinga Newsdesk
Celldex Therapeutics shares are trading lower...
Benzinga Newsdesk
Why F5 Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Avi Kapoor
Monday, July 29, 2024
Celldex Announces Phase 2 Results For Barzolv...
Benzinga Newsdesk
Sunday, July 28, 2024
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
Lekha Gupta
Tuesday, July 16, 2024
Analyst Expectations For Celldex Therapeutics's Future
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Celldex...
Benzinga Newsdesk
Celldex Therapeutics Begins Global Phase 3 Pr...
Benzinga Newsdesk
Tuesday, June 18, 2024
Cantor Fitzgerald Reiterates Overweight on Ce...
Benzinga Newsdesk
Tuesday, June 11, 2024
Wolfe Research Initiates Coverage On Celldex ...
Benzinga Newsdesk
Monday, June 03, 2024
Analyst Expectations For Celldex Therapeutics's Future
Benzinga Insights
HC Wainwright & Co. Reiterates Buy on Celldex...
Benzinga Newsdesk
Sunday, June 02, 2024
Celldex Therapeutics Reported Data Showing Barzolvolimab Improves Angioedema At 12 Weeks In Phase 2 Study For Chronic Spontaneous Urticaria
Charles Gross
Wednesday, May 15, 2024
HC Wainwright & Co. Reiterates Buy on Celldex...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch